

NATIONAL REINING HORSE ASSOCIATION
European Affiliate Council E-VOTE
April 15, 2026

Approved May 22, 2026

Members: Rosanne Sternberg (*Chair*), Paulus Beurskens, Maik Bartmann, Mariannick Domont-Perret, Isabeau Rohde, Rudi Kronsteiner, Agnes Csolle, Annette Andersen, Markus Schopfer, Adrienne Speidel, Pietro Marseglia, Bernard Fonck, Leonardo Arcese, Anna Porola, Anna Fagerlund, Tor Erik Eggen

Staff Liaison: Samantha Oldfield

Motion to approve the following changes to the NRHA Medications Policy for the NRHA European region to go to the NRHA Board of Directors (or Executive Committee) for review:

- Only allow Altrenogest in mares.
- Alpha Casozepine (Zylkene)- Keep Banned
- Cetirizine- Keep Conditionally Permitted
- Dimethyl Sulfoxide (DMSO)- Keep Conditionally Permitted
- Ipratropium)- Keep Conditionally Permitted
- Levothyroxine)- Keep Conditionally Permitted
- Salicylic acid (Aspirin)- Keep Conditionally Permitted
- All cannabinoids (synthetic and natural)- Keep banned
- Diclofenac (Surpass): Increase dose to 0.010 µg/ml- Keep at previous threshold
- Firocoxib: Increase dose to 0.057 mg/lb (57 mg/1,000 lbs)- Keep at previous threshold

With the understanding that Romifidine is already banned in the European region in NRHA competition.


Support	Oppose	Abstain	No Response	Call for Discussion
15 13 responded via survey, 2 via digital communication	0	0	1	0

Q1 13 responses



Horizontal bar ▼

Please submit your vote—support, oppose, abstain, or call for discussion—regarding the memorandum with the task force recommendation on the NRHA medications policy updates and the NRHA European region.



Answer Choices ↓	Percentage ↓	Responses ↓	
Support	100.00%	13	...
Oppose	0%	0	...
Abstain	0%	0	...
Call for Discussion	0%	0	...
Total		13	